Tai-Chong Announces Board Approval of Exclusive Licensing Agreement with Subsidiary TCM Life Science Inc. for U101
NQ Score
87/100
N1 Content Completeness
9
AI Summary (NQ-processed)
Tai-Chong's Board of Directors has approved an exclusive licensing agreement with its U.S. subsidiary, TCM Life Science Inc., granting global development, manufacturing, and commercialization rights for U101. The total deal value, including milestone payments, amounts to USD 750 million.
AI Analysis
Frequently Asked Questions
- Q: Who is the licensee of U101?
- A: TCM Life Science Inc., a 100%-owned U.S. subsidiary of Tai-Chong.
- Q: What is the duration of the U101 license?
- A: The longer of the patent life or ten years post-approval in each region.
- Q: When does the agreement become effective?
- A: Upon receipt of funding or sublicense revenue by TCM Life Science Inc.
- Q: What is the total value of the deal?
- A: USD 750 million, including development and sales milestones.
- Q: What is the strategic purpose of this agreement?
- A: To accelerate global clinical development and commercialization of U101.